Patents by Inventor Govind Ragupathi
Govind Ragupathi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230219991Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: March 8, 2023Publication date: July 13, 2023Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20210283248Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: April 25, 2018Publication date: September 16, 2021Applicants: Adjuvance Technologies, Inc., Memorial Sloan Kettering Cancer CenterInventors: Philip LIVINGSTON, Govind RAGUPATHI, Jeffrey GARDNER, J Tyler MARTIN
-
Publication number: 20210236630Abstract: The present disclosure provides methods for enhancing the immunogenicity of a poorly immunogenic antigen-specific vaccine as well as methods for promoting diversification of the gut microbiome in a subject in need thereof comprising administering to the subject an effective amount of a beta-glucan extract derived from yeast. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: April 23, 2019Publication date: August 5, 2021Inventors: Nai-Kong CHEUNG, Shakeel MODAK, Govind RAGUPATHI
-
Patent number: 10906926Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: GrantFiled: March 23, 2020Date of Patent: February 2, 2021Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCERInventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
-
Publication number: 20210002316Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: August 27, 2020Publication date: January 7, 2021Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20200239509Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: March 23, 2020Publication date: July 30, 2020Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20190048073Abstract: The present invention provides for anti-GD3 antibodies, and ADCs and methods for preparing and using the same.Type: ApplicationFiled: July 19, 2018Publication date: February 14, 2019Inventors: Faical Miyara, Dhanvanthri S Deevi, Lioudmila Tchistiakov, Michelle Mader, Yijie Gao, Paul Chapman, Govind Ragupathi
-
Publication number: 20180327436Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: November 4, 2016Publication date: November 15, 2018Applicant: ADJUVANCE TECHNOLOGIES, INC.Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Patent number: 9598466Abstract: Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.Type: GrantFiled: July 13, 2009Date of Patent: March 21, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Jianglong Zhu, Dongjoo Lee, Philip Livingston, Govind Ragupathi
-
Patent number: 9493580Abstract: Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.Type: GrantFiled: June 10, 2011Date of Patent: November 15, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Govind Ragupathi, Philip O. Livingston, Jianglong Zhu, David R. Spriggs
-
Publication number: 20150086585Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: ApplicationFiled: September 24, 2014Publication date: March 26, 2015Inventors: David GIN, Michaelle ADAMS, Kai DENG, Nicholas PERL, Annie WON, Philip LIVINGSTON, Govind RAGUPATHI
-
Publication number: 20150023954Abstract: Methodologies and technologies for potentiating antibody-based cancer treatments by increasing complement-mediated cell cytotoxicity are disclosed. Further provided are methodologies and technologies for overcoming ineffective treatments correlated with and/or caused by sub-lytic levels of complement-activating monoclonal antibodies (“mAb”) against cancer antigens or cancer antigens with low tumor cell density. While detectable levels of passively administered or vaccine-induced mAb against some antigens are able to delay or prevent tumor growth, low levels of mAb induce sublytic levels of complement activation and accelerate tumor growth. This complement-mediated accelerated tumor growth initiated by low mAb levels results in activation of the PI3K/AKT survival pathway. Methodologies and technologies relating to administration of PI3K inhibitors to overcome low dose mAb-initiated, complement-mediated PI3K activation and accelerated tumor growth are disclosed.Type: ApplicationFiled: March 14, 2013Publication date: January 22, 2015Inventors: Xiaohong Wu, Wolfgang W. Scholz, Govind Ragupathi, Philip O. Livingston
-
Patent number: 8889842Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: GrantFiled: September 13, 2012Date of Patent: November 18, 2014Assignee: Sloan-Kettering Insititute for Cancer ResearchInventors: David Y. Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
-
Publication number: 20130095173Abstract: Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.Type: ApplicationFiled: June 10, 2011Publication date: April 18, 2013Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Govind Ragupathi, Philip O. Livingston, Jianglong Zhu, Karthik Iyer, Guangbin Yang
-
Publication number: 20130011421Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: ApplicationFiled: September 13, 2012Publication date: January 10, 2013Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
-
Patent number: 8283456Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: GrantFiled: April 8, 2009Date of Patent: October 9, 2012Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
-
Publication number: 20110300177Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: ApplicationFiled: April 8, 2009Publication date: December 8, 2011Inventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
-
Publication number: 20110229510Abstract: Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.Type: ApplicationFiled: July 13, 2009Publication date: September 22, 2011Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Jianglong Zhu, Qian Wan, Insik Jeon, Woohan Kim, Pavel Nagorny, Dongjoo Lee, Philip Livingston, Govind Ragupathi
-
Publication number: 20080241195Abstract: This invention provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of: a) selection of an appropriate cancer cell line; and b) detection of the expression of antigens on the surface of said cell line of the cancer, wherein the antigens expressed will be used in the polyvalent vaccine. This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of : a) selection of an appropriate cancer cell line and b) detection of the immunogenicity will be used in the polyvalent vaccine. This invention provides various uses of the identified polyvalent vaccine.Type: ApplicationFiled: October 6, 2006Publication date: October 2, 2008Inventors: Philip O. Livingston, Govind Ragupathi